As weight loss drugs like Ozempic and Wegovy become popularized by pill-pushing allopathic doctors, new evidence suggests there are serious, life-altering risks with these new drugs. According to a new study, Ozempic an Wegovy users are at an elevated risk of developing a “potentially blinding eye condition.” This is what happens when you inject reptile venom peptides.
Venomous Ozempic and Wegovy increase risk of blindness
The study, published in JAMA Ophthalmology, has raised concerns about an association between semaglutide, a medication used to manage type 2 diabetes and obesity, and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) This serious condition (NAION) can lead to sudden vision loss and is characterized by damage to the optic nerve.
The study, led by Jimena Tatiana Hathaway, MD, MPH and colleagues, investigates a link between semaglutide use and the incidence of NAION. The researchers conducted a retrospective matched cohort study using data from a centralized registry covering patients who were evaluated by neuro-ophthalmologists at an academic institution between December 2017 and November 2023.
The study included 16,827 patients who had no prior history of NAION. Among these, 710 patients had type 2 diabetes (T2D) and 979 were overweight or obese. Within these groups, patients were either prescribed semaglutide or non–glucagon-like peptide receptor agonist (GLP-1 RA) medications for managing their conditions.
“The study found people with diabetes who had been prescribed semaglutide by their physician and then filled the prescription were more than four times more likely to be diagnosed with NAION,” the authors wrote in a press release, adding, “Those who were overweight or obese and were prescribed this drug were more than seven times more likely to get the diagnosis.”
Hellbound and Down 